

## Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes- Gender Differentiation in Determinants

Aleksandra Trojak\*

Department of Metabolic Diseases, CM Jagiellonian University, Cracow, Poland

### Abstract

Nonalcoholic fatty liver disease (NAFLD) is recognized in 20-30% of general population but among the people with impaired glucose metabolism this fracture is about 70-90%. There are numerous pieces of research proving significant differentiation of various risk factors of diseases among men and women. The aim of this study is to estimate differences in NAFLD determinants with respect to patients' sex. In this study 184 patients were examined, 77 women and 107 men. Based on statistic analysis it was found out that sex is significant determinant of NAFLD.

**Keywords:** Nonalcoholic fatty liver disease; Gender as NAFLD determinant

### Introduction

Nonalcoholic fatty liver disease is a very common worldwide spread disease. The prevalence of NAFLD in general population is around 20-30% [1], whereas among patients with type 2 diabetes is up to 70-90% [2]. The connection between sex and prevalence of fatty liver disease was not widely examined so far. Few piece of research on this subject reports that there are differences in expression of metabolic syndrome between men and the women, especially in body fat distribution and adiposity function and the body weight [3]. The direction and strength and correlation between NAFLD and their determinants in respect of patient's sex was determined in this study.

### Material and Methods

184 patients (77 women and 107 men) with type 2 diabetes were examined. All patients were hospitalized in Metabolic Diseases Clinic of Jagiellonian University, Cracow, Poland from 2011-2012. All patients were asked about their medical history and alcohol consumption. People that defined themselves as alcohol drinkers or drink more than 30 g of ethanol daily (or equivalent), were excluded from the study. All participants underwent physical examination and laboratories tests were done too.

Glycemic control, chronic diabetes complications were also performed. Body mass index (BMI) was calculated by dividing the weight in kilograms by the height in meters squared. All patients had blood presser measured at least twice a day. HbA1c levels in % were measured using HPLC method. The estimated glomerular filtration rate (eGFR) were calculated using the formula reported by European Society of Nephrology. Plasma liver enzymes, and other biochemical blood measurements were determined by standard procedures. Diabetes macroangiopathy as coronary heart disease (CHD) or cerebrovascular diseases was diagnosed based on previous medical history.

Descriptive statistic methods and linear regression with heteroscedasticity correction were used because of the specific characteristic of the data. Various medical and statistical journal suggest this method as a credible way of heteroscedasticity elimination [4,5].

### Results

Characteristics of the studied group is presented on Table 1.

As mentioned before 184 consecutive type 2 diabetes patients from diabetes clinic, 77 of them women and 107 men. Average age of patients was 50.5+/-11.6 in men group and 50.8 +/- 11.2 in women (p=0.771). The waist/hips ratio (WHR) was 1.014 in men and 0.921 in women group- this difference was statistically significant (p<0.001).

After estimation of the analyzed parameters with using linear

Feature analysed	Group N=184	Men N=107	Women N=77	p
	x (sd) / Me (IR)	x (sd) / Me (IR)	x (sd) / Me (IR)	
Age	50.5 (11.6)	50.3 (11.8)	50.8 (11.2)	0.771
How long diabetes lasts(years)	11.3 <sup>^</sup> (7.6)	11.7 <sup>^^</sup> (7.7)	10.8 <sup>^^^</sup> (7.3)	0.444
SBP	126.8 (13.6)	128.6 (15.0)	124.3 (11.1)	0.038
DBP	78.6 (9.3)	79.3 (9.9)	77.7 (8.5)	0.246
GFR	77.7 (29.1)	80.1 (30.6)	74.3 (26.7)	0.192
Waist circumference	105.3 (16.4)	107.2 (15.4)	102.4 (17.6)	0.076
Hips circumference	107.7 (13.0)	105.6 (10.8)	111.0 (15.4)	0.011
WHR	0.978 (0.099)	1.014 (0.097)	0.921 (0.074)	<0.001
BMI	31.7 (6.3)	31.6 (6.0)	31.9 (6.9)	0.741
HbA1c	8.88 (2.15)	8.64 (1.82)	9.19 (2.50)	0.105
ALAT*	27 (21)	30 (24)	23.5 (17)	0.001
ASPAT*	23 (15)	25 (16)	21 (8)	0.014
Total cholesterol	4.6 (1.9)	4.5 (2.0)	4.7 (1.3)	0.187
LDL	2.61 (1.06)	2.54 (1.10)	2.72 (1.00)	0.269
HDL	1.11 (0.35)	1.09 (0.37)	1.14 (0.34)	0.316
TG*	1.60 (1.30)	1.58 (1.40)	1.70 (1.50)	0.330
GGTP*	36 (35)	39 (35)	34 (35)	0.139
FA*	75 (49)	74 (56)	76 (50)	0.517
Creatynine	74 (30)	79.5 (28.3)	61 (24.2)	<0.001

Table 1: General characteristic of the group.

\*Corresponding author: Aleksandra Trojak, Department of Metabolic Diseases, CM Jagiellonian University, Cracow, Poland, Tel: 793 773 242; E-mail: [stomporek@yahoo.co.uk](mailto:stomporek@yahoo.co.uk)

Received June 27, 2014; Accepted November 27, 2014; Published November 29, 2014

Citation: Trojak A (2014) Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes- Gender Differentiation in Determinants. J Diabetes Metab 6: 476 doi:10.4172/2155-6156.1000476

Copyright: © 2014 Trojak A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Variable	men			women		
	coefficient	p value	significance	coefficient	p value	significance
Const	-10,4537	0,00154		-0,153951	0,96959	
Diabetes in years	-0,00838039	0,10602		-0,0123341	0,05773	*
Units of insulin/24h	0,00148177	0,07639	*	0,00114264	0,28195	
Hips	-0,0555369	0,03751	**	-0,070794	0,01427	**
Waist	0,0566156	0,02718	**	0,0794853	0,00185	***
BMI	0,104982	0,02993	**	-0,103097	0,11322	
HbA1c	-0,000438683	0,97582		0,0513171	0,01139	**
LDL	-0,00296785	0,91247		-0,0751049	0,09411	*
HDL	-0,167609	0,06172	*	-0,51932	<0,00001	***
TG	0,00187272	0,64342		-0,00431464	<0,00001	***

Table 2: The results of estimation with NAFLD as dependent variable.

regression with heteroscedasticity correction (Table 2), it was found out that in women group there existed statistically significant connection between the metabolic control and prevalence of NAFLD ( $p=0.0113$ ). This kind of correlation was not observed in men group. In men group however it was found strong positive relationship between BMI and NAFLD ( $p=0.0299$ ) – in spite of the similar BMI in both sex group. In both groups we observed positive relation between waist circumference and presence of NAFLD.

In women group statistically significant correlation between the level of HDL- cholesterol and prevalence of NAFLD were observed. Such relationships were not seen in men group.

## Discussion

This study characterized the clinical and biochemical features of type 2 diabetic patients with and without NAFLD with respect of sex.

In analyzed group positive relation between waist circumferences and presence of NAFLD were observed ( $p=0.271$  for men and  $p=0.01427$  for women). The presence of NAFLD is strongly connected with metabolic syndrome (5) and one of its criteria is waist circumference above the norm in European population – over 80 cm for women and 94 cm for men [6]. A bigger waist circumference indicates more visceral adipose tissue.

As the reason of insulin resistance in visceral adipose tissue we observed local inflammation. It causes releasing a lot of chemical substances such as free fatty acids, TNF- $\alpha$  or chemotactic monocytes type 1 protein [7]. These substances are pro-inflammatory precursors and could increase local insulin resistance. Insulin resistance is pathogenic risk factor of developing or progressing NAFLD. In type 2 diabetes patients we observed severe metabolic disturbances such as hyperglycemia, dyslipidemia, subclinical inflammation, thrombosis and oxidative stress [8].

In women group the hip circumferences was negatively correlated with NAFLD ( $p=0.0018$ ). We also recognized the same peculiarity in men group, but the statistical significance of this correlation was lower ( $p=0.03751$ ).

It is known that HDL- cholesterol plays significant role and has several functions in our body. HDL - C are very heterogenic group and have several additional protective properties that are independent. For example, they have properties that reduce oxidation, vascular inflammation and thrombosis [9]. Other parts improve endothelial function, promote endothelial repair. What is more, some particles enhance insulin sensitivity and promote insulin secretion by pancreatic beta islet cells [10]. It can be the reason why in women group, in which

the level of HDL-C is higher ( $p<0,001$ ) fatty liver diseases were rarely observed. The HDL-C has negative impact on NAFLD. However, the cause and effect of these differences are unclear and further investigations in this area are necessary.

In men positive relation between BMI and NAFLD was observed ( $p=0.0299$ ). Such correlations in women group was not seen, even though the level of BMI was the same in both groups.

The level of metabolic control expressed by HbA1c is an important factor of fatty liver disease in women group, but not in men group. It can prove the negative influence of hyperglycemia in women as hyperglycemia reduces the protective effect of estrogen in women [11,12].

This study bears some limitations: first of all the group of patients examined was small. Secondly, the patients in our study come from the same diabetic clinic, so the group was not random.

## Conclusion

Basing on regression analysis, the waist circumference in both sex groups and metabolic control as well as HDL cholesterol in women group are the determinants of NAFLD. What is more, the sex is also the determinant of NAFLD.

## References

- Petta S, Muratore C, Craxi A (2009) Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver dis 41: 615-625.
- Marchesini G, Moscatiello S, Di Domizio S, Forlani G (2008) Obesity-associated liver disease. J Clin Endocrinol Metab 93: S74.
- Pradhan AD (2014) Sex differences in metabolic syndrome: implications for cardiovascular health in women. Clin Chem 60: 44-52.
- Kotronen A, Yki-Jarvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arther. Thromb Vasc Boil 28: 27.
- Szczeklik A (2013) Interna- podręcznik chorób wewnętrznych, Kraków.
- Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, et al. (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17: 4.
- King GL (2008) The role of inflammatory cytokines in diabetes and its complications. J Periodontal 79: 1527.
- Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, et al. (2007) Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 13: 1579.
- Cysneiros FJA, Cordeiro GM, Cysneiros AHMA (2010) Corrected maximum likelihood estimators in heteroscedastic symmetric nonlinear models, Journal of Statistical Computation and Simulation 80.
- Stein O (1999) Athero protective mechanism of HDL. Atherosclerosis 144: 285-301.

11. Barter P (2011) HDL-C: role as a risk modifier. *Atheroscler* 12: 267-270. in cardiovascular and metabolic risk profiles among men and women with type 2 diabetes? *Diab. Med* 27: 1212-1214.
12. Sridharan S, Gunathilake W, Fernando DJ, Idris I (2012) Are there differences